Over-expression of Decoy Receptor 3 in Gastric Precancerous Lesions and Carcinoma

References

• Ozoren N, El-Deiry WS. (2003). Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol. 13:135–147.
   PubMed Web of Science ®Google Scholar
• Pith RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ,Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, God-dard AD, Botstein D, Ashkenazi A. (1998). Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 396: 699–703.
   PubMed Web of Science ®Google Scholar
• Wang S, El-Deiry WS. (2003). TRAIL and apoptosis induction by TNF-family death receptors.Oncogene. 22:8628–8633.
   PubMed Web of Science ®Google Scholar
• Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, LiuQ, Austin CP, Caskey CT. (2000). Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA. 97: 1230–1235.
   PubMed Web of Science ®Google Scholar
• Chen G, Luo DZ, Wang Y, Liao ZL, Zhang MY. (2007).Relationship between expression of de-coy receptor 3 and apoptosis in hepatocellular carcinoma. Chin J Pathol . 36: 113–117.
   Google Scholar
• Fujita Y, Sakakura C, Shimomura K, Nakanishi M, Yasuoka R, Aragane H, Hagiwara A, Abe T,Inazawa J, Yamagishi H. (2003). Chromosome arm 20q gains and other genomic alterations in esophageal squamous cell carcinoma, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Hepatogastroenterology. 50:1857–1863.
   Google Scholar
• Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY. (2005).Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esopha-gus. Am J Clin Pathol. 124: 282–287.
   PubMed Web of Science ®Google Scholar
• Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bahr M, Ohgaki H, Ashkenazi A, Weller M. (2001).Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. 61:2759–2765.
   PubMed Web of Science ®Google Scholar
• Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mi-zuno T, Nakajima Y. (2002).The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer. 5: 61–68.
   PubMedGoogle Scholar
• Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, Nakajima S, Kobayashi H, Koizumi M, Toyoda E, Ito D, Kami K, Mori T, Fujimoto K, Doi R, Imamura M.(2003).Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic ad-enocarcinoma. Int J Cancer. 106: 17–25.
   Google Scholar
• Simon I, Liu Y, Kra11 KL, Urban N, Wolfert RL, Kim NW, McIntosh MW. (2007).Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovar-ian cancer. Gynecol OncoL 106: 112–118.
   PubMed Web of Science ®Google Scholar
• Tahara E. (2004).Genetic pathways of two types of gastric cancer. IARC Sci PubL 157:327–349.
   PubMedGoogle Scholar
• Matysiak-Budnik T, Mégraud F. (2006).Helicobacter pylori infection and gastric cancer. Eur J Cancer. 42:708–716.
   PubMed Web of Science ®Google Scholar
• Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW. (2002).The long term results of endoscopic surveillance of premalignant gastric lesions. Gut. 50: 378–381.
   Google Scholar
• You WC, Zhang L, Gail MH, Li JY, Chang YS, Blot WJ, Zhao CL, Liu WD, Li HQ, Ma JL, Hu YR, Bravo JC, Correa P, Xu GW, Fraumeni JF Jr. (1998).Precancerous lesions in two counties of China with contrasting gastric cancer risk. Int J Epidemiol. 27: 945–948.
   PubMed Web of Science ®Google Scholar
• You WC, Blot WJ, Li JY, Chang YS, Jin ML, Kneller R, Zhang L, Han ZX, Zeng XR, Liu WD. (1993).Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res. 53 :1317–1321.
   PubMed Web of Science ®Google Scholar
• Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K, Riddell RH, Sipponen P, Wata-nabe H. (2000).Gastric dysplasia: the Padova international classification. Am J Surg PathoL 24: 167–176.
   PubMed Web of Science ®Google Scholar
• Wang LD, Shi ST, Zhou Q, Goldstein S, Hong JY, Shao P, Qiu SL, Yang CS. (1994).Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer 59: 514–519.
   PubMed Web of Science ®Google Scholar
• Fenoglio-Preiser C, Munoz N, Carneiro F. (2000).Tumors of the stomach. In: Hamilton SR, Aaltonen LA. World Health Organization classification of tumours, Pathology and genetics of tumours of the digestive system. 1st ed Lyon: International Agency for Research on Cancer. 37–38.
   Google Scholar
• UICC. (1997). TNM Classification of Malignant Tumors.5ed. New York: Wiley-Liss.
   Google Scholar
• Miao XP, Li JS, Li HY, Zeng SP, Zhao Y, Zeng JZ. (2007).Expression of ornithine decarboxylase in precancerous and cancerous gastric lesions. World J Gastroenterol. 13: 2867–2871.
   PubMed Web of Science ®Google Scholar
• Zhang J, Salcedo TW, Wan X, Ullrich S, Hu B, Gregorio T, Feng P, Qi S, Chen H, Cho YH, Li Y, Moore PA, Wu J. (2001).Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest. 107: 1459–1468.
   PubMed Web of Science ®Google Scholar